CAS NO: | 1613695-14-9 |
生物活性 | SGC-CBP30 is a potent and highly selectiveCBP/p300bromodomain(Kds of 21 nM and 32 nM forCBPandp300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain ofBRD4[BRD4(1)]bound. SGC-CBP30 strongly reduces secretion ofIL-17Ain Th17 cells and has anti-inflammatory effects[1][2][3]. | ||||||||||||||||
IC50& Target | CBP/p300 bromodomain[1][3] | ||||||||||||||||
体外研究 (In Vitro) | In ankylosing spondylitis and psoriatic arthritis condition, SGC-CBP30 inhibits IL-17A secretion by Th17 cells. Transcriptional profiling of human T cells after SGC-CBP30 treatment shows a much more restricted effect on gene expression than that observed with the pan-BET (bromo and extraterminal domain protein family) bromodomain inhibitor JQ1[1]. | ||||||||||||||||
体内研究 (In Vivo) | SGC-CBP30 treatment slightly alleviates alveolar bronchial fibrosis induced by NSC-125066. SGC-CBP30 plus CQ-061 dramatically reduces alveolar bronchial fibrosis. The ELISA of cytokines IL-4 and IFN-γ in BALF demonstrates that combination of SGC-CBP300 and CQ-061 suppresses the activation of IL-4 as well as IFN-γ in NSC-125066 induced IPF murine models to nearly normal levels[2].
| ||||||||||||||||
分子量 | 509.04 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C28H33ClN4O3 | ||||||||||||||||
CAS 号 | 1613695-14-9 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 31 mg/mL(60.90 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |